Remdesivir - An Important First Step

Affiliations

¹ From the Department of Medicine, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center (R.D.); and Massachusetts General Hospital, Partners AIDS Research Center (M.S.H.) - both in Boston.

Editorial

Raphael Dolin et al. N Engl J Med. 2020.

. 2020 Nov 5;383(19):1886-1887.

doi: 10.1056/NEJMe2018715. Epub 2020 May 27.

¹ From the Department of Medicine, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center (R.D.); and Massachusetts General Hospital, Partners AIDS Research Center (M.S.H.) - both in Boston.

No abstract available

Comment on

Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Beigel JH, et al. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. N Engl J Med. 2020. PMID: 32445440 Free PMC article. Clinical Trial.
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A; GS-US-540-5773 Investigators. Goldman JD, et al. N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27. N Engl J Med. 2020. PMID: 32459919 Free PMC article. Clinical Trial.

1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2007764. - DOI - PubMed
1. FDA issuance of emergency use authorization for potential COVID-19 treatment. Press release of the Food and Drug Administration, May 1, 2020. (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...).
1. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2015301. - DOI - PMC - PubMed
1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720. - PMC - PubMed
1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034. - PMC - PubMed